Adamis Pharmaceuticals Corp·4

May 22, 5:19 PM ET

Daniels Karen K. 4

4 · Adamis Pharmaceuticals Corp · Filed May 22, 2019

Insider Transaction Report

Form 4
Period: 2019-05-20
Daniels Karen K.
Vice President of Operations
Transactions
  • Sale

    Common Stock

    2019-05-20$1.73/sh5,591$9,670174,353 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted in March 2019.
  • [F2]The shares were sold to satisfy the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.81, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Documents

1 file
  • 4
    primary_01.xmlPrimary

    PRIMARY DOCUMENT